Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2014 3
2015 2
2016 2
2017 2
2019 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Lieberman PL, et al. Among authors: rahmaoui a. J Allergy Clin Immunol. 2017 May;139(5):1718-1719. doi: 10.1016/j.jaci.2016.12.976. Epub 2017 Mar 3. J Allergy Clin Immunol. 2017. PMID: 28268016 No abstract available.
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Saini SS, et al. Among authors: rahmaoui a. J Invest Dermatol. 2015 Jan;135(1):67-75. doi: 10.1038/jid.2014.306. Epub 2014 Jul 21. J Invest Dermatol. 2015. PMID: 25046337 Free PMC article. Clinical Trial.
Baseline characteristics of patients enrolled in EXCELS: a cohort study.
Long AA, Fish JE, Rahmaoui A, Miller MK, Bradley MS, Taki HN, Demeo AN, Tilles SA, Szefler SJ. Long AA, et al. Among authors: rahmaoui a. Ann Allergy Asthma Immunol. 2009 Sep;103(3):212-9. doi: 10.1016/S1081-1206(10)60184-6. Ann Allergy Asthma Immunol. 2009. PMID: 19788018 Clinical Trial.
The safety and interpretability of skin tests with omalizumab.
Lieberman P, Rahmaoui A, Wong DA. Lieberman P, et al. Among authors: rahmaoui a. Ann Allergy Asthma Immunol. 2010 Dec;105(6):493-5. doi: 10.1016/j.anai.2010.10.008. Ann Allergy Asthma Immunol. 2010. PMID: 21130393 No abstract available.
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Iribarren C, et al. Among authors: rahmaoui a. J Allergy Clin Immunol. 2017 May;139(5):1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038. Epub 2016 Sep 14. J Allergy Clin Immunol. 2017. PMID: 27639934 Free article.
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Saini SS, et al. Among authors: rahmaoui a. J Invest Dermatol. 2015 Mar;135(3):925. doi: 10.1038/jid.2014.512. Epub 2014 Dec 11. J Invest Dermatol. 2015. PMID: 25501032 Free article. No abstract available.